AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Metabase 30m series insight1/3/2023 ![]() ![]()
Neuvenge can potentially treat multiple cancers, including breast, bladder and colorectal. The company also has Neuvenge in its back pocket. Provenge is not the only product that Dendreon has to offer. I was also reported in the press release that additional manufacturing facilities will be opened in late 2011 in Los Angeles and Atlanta.īefore we look at the potential of the DNDN stock, let us also consider the potential of the pipeline. #METABASE 30M SERIES INSIGHT FULL#For full year 2011, the estimates were for well over one billion dollars as the manufacturing plant in New Jersey would by then have the capacity to produce the product at a level to support that much in sales. It was Oncophage, a kidney cancer vaccine produced by Antigenics, that became the world's first approved cancer immunotherapy when the Russian medical authorities approved it in April of 2008.Īs for Thursday's DNDN press release, the company issued Provenge sales estimates of between $60 and $120 million for the second half of 2010. I like the chances of a Provenge approval, although I think that by the time the treatment becomes approved in the United States, it will be long overdue. That being said, as long term data continues to demonstrate that the treatments work, they are slowly becoming more accepted by the medical field and Provenge is no exception. While indications point to an FDA approval, it is also good to realistically temper the enthusiasm by remembering that members of the FDA are humans - government officials, at that - and are just as likely to change their minds or ask for more information as anyone else out there. Keep in mind, however, that nothing is a sure thing both in regards to the stock market or the FDA. It is expected that the FDA will rule to approve Provenge, based on previous comments by the regulatory agency after mid term results were released last year. The company announced that they will file an NDA with the FDA in November and that the FDA would then be expected to act on the application by mid 2010. #METABASE 30M SERIES INSIGHT UPDATE#That's good news for investors who have long been interested in this promising sub-sector of the healthcare markets.ĭendreon (NASDAQ:DNDN) released an update on Thursday that outlined the path that the company is taking to advance its prostate cancer treatment Provenge to market. Please mention that you found the job at ClojureJobboard.Cancer immunotherapy stocks are back and may be making a strong push. Nice to have: experience in JavaScript / Typescript (our frontend is in JS and TS) Nice to have: history of open source contributions ![]() Nice to have: Experience with JDBC and database integrations Able to make good technical judgements and back them up articulately ![]() #METABASE 30M SERIES INSIGHT SOFTWARE#Solid CS background (acquired through either a CS program or shipping software in a production setting) Track record of shipping products of significant complexity Experience in Clojure or a strong desire to learn You should have strong product sensibilities and deeply care about the end user experience. Some familiarity with machine learning, compiler theory and modern big data infrastructures would be helpful. You’ll be expected to ship major features end to end across our JavaScript and Clojure codebase, as well as deal with some of our trickier backend issues as they arise. #METABASE 30M SERIES INSIGHT CODE#We run on a mix of Clojure and JavaScript, and the ideal candidate has shipped production code in one or more of these languages. We’re looking for exceptional software engineers to join our team in doing the hard work that makes our users’ lives easy. And we just raised a $30M Series B to take our approach to the next level for years to come. We're relentlessly user-focused and believe in building long-term value, not short-term hacks. We're a global team (50% outside of the US), fully distributed (from Thailand to Hawaii), who gets things done asynchronously, with plenty of uninterrupted time, supporting each other to do the best work of our careers. We provide an opinionated open source starting point for how companies should measure, analyze and share their data, which is used by tens of thousands of companies. We bring data tools with the elegance and simplicity of consumer products to the crufty world of enterprise business intelligence. Metabase is the easiest way for people to get insights from their data, from tiny startups who get up and running quickly to major corporations with tens of thousands of users. Software Engineer (Backend) at Metabase Remote › □ Worldwide, 100% remote position (Posted Mar 22 2022) ![]()
0 Comments
Read More
Leave a Reply. |